CHMP backs PET agent Vizamyl for Alzheimer's disease

EMA's CHMP issued a positive opinion recommending approval of PET imaging agent Vizamyl [18F]-flutemetamol to detect beta amyloid neuritic plaque in adult patients with cognitive impairment being eval...